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Background: During neuroinflammation many chemokines alter the function of the blood-brain barrier (BBB) that
regulates the entry of macromolecules and immune cells into the brain. As the milieu of the brain is altered,
biochemical and structural changes contribute to the pathogenesis of neuroinflammation and may impact on
neurogenesis. The chemokine CCL4, previously known as MIP-1β, is upregulated in a wide variety of central
nervous system disorders, including multiple sclerosis, where it is thought to play a key role in the neuro-
inflammatory process. However, the effect of CCL4 on BBB endothelial cells (ECs) is unknown.
Materials and methods: Expression and distribution of CCR5, phosphorylated p38, F-actin, zonula occludens-1 (ZO-
1) and vascular endothelial cadherin (VE-cadherin) were analysed in the human BBB EC line hCMEC/D3 by
Western blot and/or immunofluorescence in the presence and absence of CCL4. Barrier modulation in response to
CCL4 using hCMEC/D3 monolayers was assessed by measuring molecular flux of 70 kDa RITC-dextran and
transendothelial lymphocyte migration. Permeability changes in response to CCL4 in vivo were measured by an
occlusion technique in pial microvessels of Wistar rats and by fluorescein angiography in mouse retinae.
Results: CCR5, the receptor for CCL4, was expressed in hCMEC/D3 cells. CCL4 stimulation led to phosphorylation
of p38 and the formation of actin stress fibres, both indicative of intracellular chemokine signalling. The distri-
bution of junctional proteins was also altered in response to CCL4: junctional ZO-1 was reduced by circa 60%
within 60 min. In addition, surface VE-cadherin was redistributed through internalisation. Consistent with these
changes, CCL4 induced hyperpermeability in vitro and in vivo and increased transmigration of lymphocytes across
monolayers of hCMEC/D3 cells.
Conclusion: These results show that CCL4 can modify BBB function and may contribute to disease pathogenesis.1. Introduction
Neuroinflammation is the inflammatory response to injury or infec-
tion in the brain or spinal cord (Fuster-Matanzo et al., 2013) and can lead
to either collateral damage or resolution and repair depending on disease
setting. In the context of repair, the relationship between neuro-
inflammation and neurogenesis, the process through which new neurons
are generated in the brain, is tied in with different inflammatory com-
ponents of the immune system, including chemokines, cytokines, and
immune cells.ntral nervous system; EC, endoth




is an open access article under tChemokines, expressed by an array of immune and non-immune cells,
including endothelial cells (ECs), have been shown to have a leading role
in neuroinflammation and neurodegeneration (Thuc et al., 2015; Ramesh
et al., 2013). Engagement of chemokines with their G-protein coupled
receptors results in a change in cell behaviour, including migration,
proliferation, and activation of inflammatory responses. During inflam-
mation, leukocyte engagement and recruitment across the blood-brain
barrier (BBB) is a tightly regulated process involving multiple steps
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Fig. 1. CCR5 expression in hCMEC/D3. A- Western blot of endothelial cell
lysates from HUVEC (lane 1) and hCMEC/D3 (lane 2). The position of CCR5
predicted by its molecular weight is arrowed. B – 1) CCR5 expression in
hCMEC/D3 detected by immunofluorescence showing punctate cytoplasmic
membrane staining concentrated in the periphery of each cell; Yellow box
highlights regions of images magnified in the Zoom panel 2) Zoom detail. Scale
bar: 10 μm. (For interpretation of the references to colour in this figure legend,
the reader is referred to the Web version of this article.)
C. Estevao et al. Brain, Behavior, & Immunity - Health 18 (2021) 100370closely involved in activating leukocyte adhesion and promoting subse-
quent chemotaxis and migration to the site of injury (Speyer and Ward,
2011). The functional outcome of chemokines on ECs, however, remains2
mostly unknown with only a few studies demonstrating
chemokine-enhanced BBB permeability effects (Speyer and Ward, 2011).
A principal function of the BBB is to maintain tight control over the
passage of molecules and cells to and from the central nervous system
(CNS) but under many disease conditions, including neuroinflammation,
the endothelial barrier becomes hyperpermeable. Accordingly, alter-
ations to properties of the BBB, where barrier function is compromised,
have been found in various neurological conditions such as stroke,
trauma and neurodegenerative diseases (Barzo et al., 1997; Kortekaas
et al., 2005; Zlokovic, 2005; Bell et al., 2010; Iadecola, 2010). Addi-
tionally, some of these conditions are also associated with impairments in
hippocampal neurogenesis, such as Alzheimer's disease (AD), Parkinson's
disease (PD), multiple sclerosis (MS) (Giannakopoulou et al., 2017),
stroke and other pathologies with associated neurological and cognitive
decline (Wang and Jin, 2015).
Chemokines regulate the recruitment and activation of circulating
and resident immune cells in all tissues, including the brain, and
orchestrate immune activity during acute and chronic neuro-
inflammation. The effect of some CCL chemokines on ECs has been
explored, but the contributions of the CC chemokine CCL4 (previously
known as MIP-1β) in particular, on BBB function, remains poorly un-
derstood. CCL4 overexpression in the brain has been reported in a
number of diseases including MS (Subileau et al., 2009), AD (Zhu et al.,
2014) and PD (Calvani, 2020), and as such may impact on disease pro-
gression by causing, amongst other effects, BBB dysfunction. A review on
chemokines in MS has highlighted that CCL4 appears to have a role in the
pathogenesis of the disease (Ghafouri-Fard et al., 2021). However, it is
unknown how it is mechanistically involved, and in particular how itFig. 2. - CCL4 treatments mediated p38 activa-
tion. Distribution of P–P38 in hCMEC/D3 following
CCL4 treatment (100 ng/mL). Cells were stained for
phospo-p38 and nuclear DNA. A- Images show full
projection of confocal stacks through the full thick-
ness of the cells. Scale bar 50 μm. Images were taken
on Zeiss LSM700. B - Cytosolic/nuclear phospho-
protein quantification, normalized to control. Re-
sults are expressed as average means  SEM. Sta-
tistical analysis performed using One-way ANOVA
and a Dunnet post hoc test for statistical analysis of
mean value variances. *, P < 0.05, P ¼ 0.0002,
F ¼ 11.24 and dF ¼ 19.
Fig. 3. – Stress fibre formation in response to
CCL4 treatment. hCMEC/D3 were left untreated or
treated with CCL4 (100 ng/mL) for 5, 10, 30 and
60min, fixed and immunostained for phalloidin and
nuclear DNA. A- Images show full projection of
confocal stacks through the full thickness of the
cells. Images were taken on Zeiss LSM700. Scale bar
50 μm. B - Fibre intensity mean area average  SEM
of phalloidin area/DAPI, normalized to control.
Statistical analysis used One-way ANOVA and Dun-
net post hoc test. **, 0.001<P < 0.01; ***,
P < 0.001; ****, P < 0.0001, P ¼ 0.0039, F ¼ 114.3,
and dF ¼ 19.
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The sparse current evidence has shown that CCL4 is able to induce
BBB disruption in an animal model of pneumococcal meningitis (Geeta
et al., 2013) and has also been shown to increase T cell adhesion to ce-
rebral endothelial cells (Quandt and Dorovini-Zis, 2004). Following
ICAM-1 crosslinking, the expression of CCL4 was also found to be upre-
gulated in hCMEC/D3 (Dragoni et al., 2017), suggesting that this che-
mokine can potentially be induced and act in an autocrine manner on
brain endothelial cell function during inflammation. CCL2, from the
same subfamily as CCL4, has also been strongly implicated in CNS
inflammation and has been shown to increase permeability through
disruption of adherens junctions (Dimitrijevic et al., 2006; Roberts et al.,
2012). In addition, CCL4 and CCL5 have been shown to enhance adhe-
sion of CD4þ T cells to activated brain ECs (Quandt and Dorovini-Zis,
2004). This evidence suggests that chemokine signalling in BBB endo-
thelium, specifically CCL4, could be involved in downstream effects on
permeability to macromolecules and immune cells and ultimately to the
onset and progression of neuroinflammatory conditions which, in turn,
may have direct consequences to neurogenesis.
In this study we determine in a human in vitro model of the BBB
whether CCL4 can act directly on brain endothelial cell function. We
show that CCL4 can alter BBB junctional structure and function placing
CCL4 as a potentially important contributing factor to the pathogenesis of
this structure in a wide range of neurological conditions.
2. Materials and Methods
2.1. Human brain microvascular endothelial cells (hCMEC/D3)
HCMEC/D3 (passage 26 and 35) (Weksler et al., 2005) were cultured
in EGM™-2 Basal Medium supplemented with FBS, Penicillin Strepto-
mycin (P/S) (1%), hydrocortisone (1 mg/mL), ascorbic acid3
(2.5 mg/mL), lipid concentrate, HEPES and bFGF (10 μg/mL). Cells were
seeded at 8x104 to 1x105 cells/mL in collagen I (1:60 in DPBS) coated cell
culture plates/flasks and media was changed every other day following a
DPBSwash. Cultures were grown to 75–90% confluence before passaging
and were used between passage 26 and 35. Culture mediumwas changed
every other day until cells reached 75–90% confluence for renewed
passaging. This cell line has been extensively used as a model of the BBB
in the context of neuroinflammation (Lopez-Ramirez et al., 2013).2.2. Human umbilical vein endothelial cells (HUVEC)
HUVEC were cultured in EGM-2 medium supplemented with EGM-2
B BulletKit™ (VEGF, IGF, bFGF, hydrocortisone, ascorbate, gentamycin
and 2.5% foetal bovine serum (FBS)) as indicated by the manufacturer.
cells were seeded at 8x104 - 1x105 cells/mL in gelatine-coated cell culture
plates or flasks and media was changed every other day. Cells were
grown in a humidified atmosphere at 37 C in 5% carbon dioxide (CO2)
and up to 75–90% confluence and used between passage 2 and 5.2.3. Immunoblotting
Cells were lysed in lysis buffer (4% SDS, 10% 2-mecaptoethanol, 20%
glycerol, 0.004% bromophenol blue 0.125 M Tris HCl). Samples were
collected and denatured at 100 C for 5min and centrifuged and frozen at
20 C until further use. Alternatively, cells were lysed in RIPA buffer
with protease and phosphatase inhibitors (to avoid proteolysis and pre-
serve phosphorylation of proteins), and centrifuged. Supernatants were
further denatured using lysis buffer. Sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting
were performed as previously described (Turowski et al., 1999) using
antibodies against the proteins of interest: CCR5 (Abcam) was used at
1:3,000, HSC70 (Sigma) at 1:10,000 and P–P38 MAPK (T180/Y182) at
Fig. 4. – Decrease of junction ZO-1 in response to CCL4. hCMEC/D3 were
left untreated or stimulated with CCL4 (100 ng/ml) for the indicated times
before fixation and staining for ZO-1 and nuclear DNA. A - Images show full
projection of confocal stacks through the full thickness of the cells. Images were
taken on Zeiss LSM700. Scale bar 50 μm. B - Intensity of junctional ZO-1 was
determined by average mean area of junctional ZO-1, normalized to nuclear
stain. Shown are mean normalized intensities /þ SEM. Statistical analysis used
One-way ANOVA and Dunnet post hoc test. ***, P < 0.001, P < 0.0001,
F ¼ 198.9, and dF ¼ 8.
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Systems) at 1:3000 in 0.1% PBSA. Secondary antibodies were used at
1:10,000 in 0.1% PBSA. For quantitative analyses immunoblots were
scanned and quantified using the NIH imaging software ImageJ.
2.4. Immunofluorescence
HCMEC/D3were grown on collagen I coated 35 mm2 Petri dishes and
stimulated with CCL4 for 5, 10, or 60 min, fixed in 4% paraformaldehyde
and blocked in PBSA (0.5% with sodium azide). Nuclei of cells were
visualised by the addition of 1 μg/mL Hoechst 33258 (bis-benzminide) or
DAPI in the secondary antibody staining solution. The dishes were stored
at 4 C, mounted, and imaged using the Zeiss LSM 710 confocal micro-
scope. Optionally, cells were permeabilised using ice cold acetone at
20 C. Cells were then incubated with primary and secondary antibody
at 37 C in a humidified chamber. To reveal surface VE-cadherin, per-
meabilisation was performed after the first primary antibody incubation.
Anti-Human VE-Cadherin Monoclonal Antibody (R&D Systems) and VE-
cadherin Antibody (C-19) (Santa Cruz Biotechnology) were used at
1:200, P–P38 MAPK (T180/Y182) (Cell Signalling Technology) was used
at 1:3000 and ZO-1 (Thermofisher) was used at 1:50, in 0.1% PBSA.
Secondary antibodies were used at 1:300 in 0.1% PBSA.4
2.5. Permeability measurement in hCMEC/D3
hCMEC/D3 cells were grown on 12-mm transwell filters with 0.4 μm
pore size. The technique was performed as described previously (Martins
et al., 2013). 70 kDa Rhodamine B isothiocyanate (RITC)-dextran was
added at 1 mg/mL to the apical side of the transwell filters. 50 μl samples
were collected from the basal chamber (and replaced with EBM-2 culture
media) at 15 min intervals for 180 min with our without the addition of
CCL4. Fluorescence of samples was measured in a Tecan Safire Fluores-
cence Reader, plotted against time and permeability changes were
determined from linear slope changes. Statistical analysis was done using
a two tailed Student's t-test. Analysis performed using GraphPad Prism
version 5.0 for Windows (GraphPad Software, San Diego CA USA).
Recombinant Human MIP-1β (CCL4) (used in all experiments) was
purchased from Peprotech (cat. Number 300-09). As per manufacturer's
indication, purity is  98% by SDS-PAGE gel and HPLC analyses (Re-
combinant HumanP-1β, 2021).
2.6. Primary T cells
Human CD4þ cells were isolated from peripheral blood from healthy
volunteers using Ficoll® Plaque Premium and positive selection on CD4þ
MACS beads (Miltenyi) as previously described (Martinelli et al., 2008).
CD4þT cells were resuspended in RPMI-1640 supplemented with 10%
FCS, 100 U/ml penicillin, 100 μg/ml streptomycin,1 mM sodium pyru-
vate, 1 mM nonessential amino acids, 2 mM l-Glu, and 50 μm β-mer-
captoethanol supplemented with 25 ng/mL of IL-2 at a density of 500,
000 cells/mL.
2.7. T-lymphocyte endothelial transmigration
Technique performed as previously described (Adamson, Etienne,
Couraud, Calder, Greenwood). CCL4was added to hCMEC/D3 for 30min,
washed off, and T cells resuspended in HBSS were added to the wells.
Lymphocytes were left to adhere and migrate for 30 min in an incubator
and T lymphocytes that did not adhere were gently washed off using
HBSS at 37 C. For imaging purposes, plates were mounted on a phase
contrast microscope (Zeiss 200 M). Mean migration rates and standard
mean errors were calculated from at least three independent experi-
ments. Statistical analysis was carried out using a two-tailed Student's
t-test. Analysis performed using GraphPad Prism version 5.0 forWindows
(GraphPad Software, San Diego CA USA).
2.8. In vivo permeability measurements in pial microvessels
The method used in this study, and its theoretical basis, have been
described previously (Easton and Fraser, 1994). The experiments were
performed on male Wistar rats (25–30 days) within guidelines set by The
Animals (Scientific Procedures) Act 1986 and the EU Directive
2010/63/EU guidelines for animal experiments.
The rats were anesthetised, the dura and arachnoid were removed,
thus exposing the microcirculation of the surface of the brain and leaving
it free of any diffusion barrier towards the superfusing solution. Sulfo-
rhodamine B was added to the brain microcirculation into the carotid
artery and viewed under 540/25 nm illumination. The signal was
captured through a microscope coupled to an image-intensifier camera
(Hamamatsu). Video microscopy (1 frame per 2s) recorded the time-
dependent loss of dye in a single vessel, occluded by a glass probe. A
baseline recording was established for 20–60 s. To obtain measurements,
the flow of superfusing solution was stopped so that a pool was formed
between the brain and the microscope's water immersion lens. Dye was
injected into the circulation and the probe was placed over the vessel to
be analysed. Remaining dye in the circulation was removed by the blood
flow. For the abluminal CCL4 additions, the compounds were applied to
the pool on the brain surface. Image analysis and densitometry was
performed using ImageJ 1.45s (NIH). At the end of the experiment
Fig. 5. – Decrease in VE-cadherin in response to
CCL4. hCMEC/D3 were left untreated or treated
with CCL4 (100 ng/mL) for 5, 10 and 60 min, fixed
and stained for VE-cadherin and nuclear DNA. A-
Images show full projection of confocal stacks
through the full thickness of the cells. Images were
taken on Zeiss LSM700. Scale bar 50 μm (top row) or
10 μm (middle and bottom row). B - Mean area
average  SEM of VE-cadherin stain, expressed as
VE-cadherin fold change. Statistical analysis used a
One-way ANOVA and Dunnet post hoc test.
*p < 0.05. P ¼ 0.0462, F ¼ 3.992, and dF ¼ 15. C –
Western blot and analysis of total VE-Cadherin.
Normalized Mean VE-cadherin  SEM, normalized
to HSC70 is shown as fold change. Statistical anal-
ysis used a One-way ANOVA and Dunnet post hoc
test.
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The mean pixel intensity was measured for each vessel tested for each
frame/2 s and plotted against time. Data was normalized to diameter of
the vessel according to pre-set graticule that correlates vessel diameter in
a 20x Olympus field (used for the experiment) with 10 μm grid. Mean
pixel intensity before and after addition and corresponding SEM were
calculated and a paired t-test was used to compare differences between
the two time sets (before and after additions).2.9. Intravitreal injections and fundus fluorescein angiography
Experiments performed on adult C57BL/6Jmice within guidelines set
by The Animals (Scientific Procedures) Act 1986 C57BL/6J and the EU
Directive 2010/63/EU guidelines for animal experiments.
Adult C57BL/6J animals were anaesthetised using an intra-peritoneal
injection of Ketamine (60 mg/kg) and Domitor® (10 mg/kg). For intra-
vitreal injections, 1 μL of CCL4 (at 1 mg/mL diluted in 0.1% PBSA) to
give a final dose of 1 μg per eye. Control animals received 1 μL of vehicle.
FFA was carried out 10 min following CCL4 injections using a Micron III:
pupils were dilated with 1% tropicamide, eyes kept moist with Visco-
tears®, and light fundus images acquired followed by green fluorescence5
images at 1.5 and 7 min following subcutaneous injection of 2% fluo-
rescein. Statistical analysis carried out using Student's t-test for variance
of mean values.
3. Results
3.1. CCR5 expression in hCMEC/D3
The expression of CCR5, the main receptor for CCL4 (Rottman et al.,
1997), was examined in the brain microvascular endothelial cell line
hCMEC/D3 and HUVEC using specific antibodies. Immunoblots of whole
cell hCMEC/D3 lysates revealed a protein band, which co-migrated with
a band in HUVEC lysates and at the predictedmolecular mass of 40.6 kDa
for CCR5 (Fig. 1A). Furthermore, when used in indirect immunofluo-
rescence the CCR5 antibody revealed strong staining in hCMEC/D3,
which was concentrated in the cell periphery (Fig. 1B).3.2. CCL4 treatment mediates p38 activation
P38 mitogen-activated kinase is a key regulator of neurovascular
barrier function (Dragoni et al., 2017; Hudson et al., 2014). Stimulation
Fig. 6. - CCL4 significantly reduces VE-Cadherin signal from the plasma membrane. VE-cadherin expression following CCL4 treatments for 5-, 10-, 30- and 60-
min. Confluent hCMEC/D3 were left untreated or were treated with CCL4 (100 ng/mL) for the above mentioned timepoints, stained for the extracellular epitope of VE-
cadherin and nuclear DNA. A - Images show full projection of confocal stacks through the full thickness of the cells. Images were taken on Zeiss LSM700. Scale bar
50 μm.
B- Experimental detail: single endothelial cell and primary (green) and secondary antibodies (grey).
C-– Mean area average  SEM of VE-cadherin stain, normalized to control. Statistical analysis used One-way ANOVA and Dunnet post hoc test. *, P  0.05; **,
P  0.01. P ¼ 0.0095, F ¼ 4.512, and dF ¼ 32.
D - VE-cadherin expression following CCL4 treatments for 5, 10, 30 and 60
min
hCMEC/D3 were left untreated or were treated with CCL4 (100 ng/mL) for the above mentioned timepoints, stained for the extracellular epitope of VE-cadherin,
intracellular epitope (C-19) and nuclear DNA. VE-cadherin Z stacks were taken on Zeiss LSM700 using a 63x and a 10x objective. A - Images show full projection
of confocal stacks through the full thickness of the cells. Images were taken on Zeiss LSM700. Scale bar 20 μm (top row only) or 50 μm.
E 
Experimental detail: single endothelial cell, and primary (green and red) and secondary (grey) antibodies.
F - JACoP plugin on image J was used to calculate the coefficient between the red/green channels for pixel co-localis
ation in 10x
images. Statistical analysis performed using a One-way ANOVA and Dunnet post hoc test. *, P  0.05. analysis performed using a One-way ANOVA and Dunnet post
hoc test. ***, P < 0.001. P ¼ 0.0001, F ¼ 28.19, and dF ¼ 11. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web
version of this article.)
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a rapid induction at 5- and 10-min post CCL4 treatment and a return to
control levels at 60 min (Fig. 2A). Accumulation of phospho-p38 was
observed both in cytoplasm and nucleus, but notably significantly more
marked in the nucleus, especially at 5min post treatment, demonstrating
that CCL4 induced activation of this key signalling molecule at the BBB
(Fig. 2B).3.3. Stress fibre formation in response to CCL4 treatment
In most cells, including ECs, p38 activation results in the induction of6
stress fibre formation (Huot et al., 1997). Stress fibres are part of the actin
cytoskeleton on ECs and allow for morphological change to occur in
response to stimuli (Schnittler et al., 2014). Stress fibres, specifically,
cytoplasm transversing actin fibres form in the endothelium when it
becomes activated in inflammatory conditions, wound healing and other
situations where homeostasis is compromised (Schnittler et al., 2014;
Abu Taha, Schnittler).
Therefore, we next assessed whether CCL4 induced stress fibre for-
mation. Strong stress fibres were observed in hCMEC/D3 following
treatment with CCL4 (Fig. 3A). The induction time course of F-actin was
very similar to that of phospho-p38, with a significant increase from
Fig. 7. - CCL4 induces neurovascular barrier
breakdown in vitro and in vivo. A -Trans-
endothelial flux changes in response to CCL4 in
hCMEC/D3. Transendothelial flux was measured in
confluent hCMEC/D3 grown in collagen coated
transwells over a period of 180 min. Response to
apical 0.1% PBSA (Control), Thrombin (1U/ml) and
CCL4 (100 ng/mL). Data represents the mean slope
change after addition of treatments. Means  SEM of
four independent experiments. *, P < 0.05.
B - In vivo measurements of permeability in pial
microvessels following CCL4 addition. Mean
permeability change in response to abluminal
administration of CCL4 (50 μg/mL). Data are
means  SEM of at least 7 vessels in three adult male
Wistar rats. *, P < 0.05. Statistical test carried out
using paired Student t-test.
C - Fluorescein leakage following CCL4 intravitreal
injection. Mice injected with CCL4 (10 μg/mL,
intravitreal injection) 15 min prior to imaging. Im-
ages obtained at 1.5- and 7-min post fluorescein in-
jection were thresholded and converted to black and
white. Pixel number was measured, and a ratio
1.5 min/7 min was calculated. Shown are
means  SEM of four C57BL/6J adult male mice.
Statistical analysis carried out using Student's t-test
for variance of mean values. Data non-significant.
D - Lymphocyte migration across hCMEC/D3
monolayer. CCL4 (100
ng/mL) was incubated with hCMEC/D3, T cells were
added and allowed to migrate. Values of migration
are expressed as mean percentages of control from at
least 4 independent experiments  SEM. Variances
of mean values were statistically analysed by the
Student's t-test. **, 0.001<P < 0.01.
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(Fig. 3B).
3.4. Decrease of junction ZO-1 in response to CCL4
To test whether CCL4 treatment altered brain EC junctions, the tight
junction associated protein ZO-1 was investigated. Treatment of hCMEC/
D3 with CCL4 resulted in a consistent alteration to the cellular distri-
bution of ZO-1, which we observed as early as 10 min post treatment
(Fig. 4A). Quantitative image analysis revealed significant reductions of
ZO-1 at the junctions by circa 30% and 60% at 10 and 60 min respec-
tively, demonstrating that CCL4 has a profound effect on a key junctional
protein (Fig. 4B).
3.5. CCL4 significantly reduces VE-Cadherin signal from the plasma
membrane
All of the above was compatible with signalling leading to endothelial
barrier dysfunction, which is specifically linked to re-distribution of the
adherens junction protein VE-cadherin (Orsenigo et al., 2012; Dragoni
et al., 2021; Wessel et al., 2014), including the interplay of VE-cadherin
and actin filaments that can be seen in junctional remodelling (Schnittler7
et al., 2014).
To test whether CCL4 induced changes in VE-cadherin, hCMEC/D3
were treated with CCL4 and VE-cadherin distribution was investigated
using several immunofluorescence protocols. Overall, there was a
gradual reduction in junctional VE-cadherin, which was significantly
reduced by approximately 50% after 60 min of CCL4 treatment (Fig. 5A
and B). However, there was no significant reduction in response to CCL4,
when VE-cadherin levels were assessed in whole cell lysates (Fig. 5C),
indicating that the reduced signal detected by immunofluorescent mi-
croscopy was due to epitope masking and/or redistribution.
To assess the level of cell surface VE-cadherin directly, live hCMEC/
D3 cells were incubated in a buffer containing the calcium chelator EGTA
to disrupt homotypic VE-cadherin. Subsequently, VE-cadherin was
detected by indirect immunofluorescence using an extracellular epitope-
specific antibody (see Fig. 6B for illustration). There was a significant
reduction in VE-cadherin signal (Fig. 6A), with significans decreases from
10 min sustained during the course of CCL4 treatment (Fig. 6C), indi-
cating a loss of VE-cadherin from the junctional cell surface.
Next, internalisation of VE-cadherin was directly assessed by com-
parison between plasma membrane localised (i.e., accessible using
extracellular specific antibodies in non-permeabilised cells) and total VE-
cadherin (stained for using a carboxy-terminal antibody following cell
Fig. 8. – Representative images for in vivo experiments. A- Fluorescein leakage following CCL4 intravitreal injection. A- Representative binary images of the
fundus fluorescein angiography of retinas of adult mice injected with CCL4. Mice injected with CCL4 (10 μg/mL, IVT injection) 15 min prior to imaging and B - In vivo
measurements of permeability in pial microvessels following CCL4 abluminal addition at 50 μg/mL.
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plasma membrane VE-cadherin staining largely overlapped (Fig. 6D),
indicating that the bulk of the protein was engaged in paracellular cell
surface junctions. Significantly, following CCL4 stimulation, staining was
detected in the channel for total VE-cadherin, which did not overlap with
the signal for surface VE-cadherin (Fig. 6D and F). Indeed, this additional
signal was observed as early as 5 min following CCL4 treatment and was
localised in close proximity to the junctions spreading towards the inside
of the cells, a localisation consistent with internalisation (Dragoni et al.,
2021).3.6. CCL4 induces neurovascular barrier breakdown in vitro and in vivo
Actin stress fibre induction and junction protein redistribution in ECs
are commonly associated with altered permeability. Thus, we examined
monolayer permeability of hCMEC/D3 cells in response to CCL4. The flux
of a 70 kDa dextran fluorescent tracer was significantly enhanced in
response to CCL4 administration albeit somewhat less than that seen in8
response to thrombin, a powerful permeability factor of ECs (Fig. 7A).
Following these results, the effects of CCL4 in vivo were investigated. A
similar, significant circa 1.5-fold increase in sulforhodamine permeability
was also observed in Wistar rat pial vessels in response to CCL4 in vivo
(Fig. 7B). Also in vivo, increased leakage as measured by fluorescein
angiography was also observed in the mouse retinal vasculature in
response to intra-ocular CCL4 injections (Fig. 7C). However, this did not
quite reach significance in 7 independent measurements. BBB barrier
breakdown to molecules often coincides with its breakdown to immune
cells (Martinelli et al., 2014). Thus, we investigated if CCL4 facilitated T
cell migration across a monolayer of ECs. For this hCMEC/D3 cells were
pre-treated or not with CCL4 and then co-cultured with CD4þ cells iso-
lated from peripheral blood. CCL4 pre-treatment resulted in a modest,
but significant, increase in T-lymphocyte transendothelial migration
(Fig. 7D).
Fig. 8 illustrates the retinal fluorescein angiography of control and
CCL4 injected mice retinas (A, representative image) and the pial
microvasculature of Wister rats, injected with VEGF (positive control)
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4. Discussion
CCL4 is considered an important chemokine in many neuro-
inflammatory conditions. However, whilst other chemokines have
demonstrated effects on the integrity of the BBB, the biological response
of BBB ECs to CCL4 has not yet been investigated. Here we show that
CCL4 induces biochemical and functional changes in BBB ECs, the
characteristics of which are consistent with BBB dysfunction.
Expression data for CCR5 in BBB ECs varies; whilst single cell RNAseq
analysis of the mouse brain vasculature reveals only very low to no CCR5
RNA expression in BBB ECs (Vanlandewijck et al., 2018), there is clear
evidence that BBB ECs express functional CCR5 (Andjelkovic and
Pachter, 2000; Edinger et al., 1997), indicating that BBB ECs possess the
machinery to respond to CCL4 stimulation. Whilst there are discrepancies
in the literature, there are several reports that indicate the human EC
cells express CCR5 (Li et al., 2013; Kanmogne et al., 2000; Maguire et al.,
2014), in addition to several reports on murine tissues (Vanlandewijck
et al., 2018; Andjelkovic and Pachter, 2000; Edinger et al., 1997). The
discrepancies in expression can be attributed to different tissues tested
and experimental methods used; nevertheless, our report confirms the
expression of CCR5 by hCMEC/D3, a cell line derived from human
temporal lobe microvessels.
Both stress fibre induction and structural and functional changes to
endothelial cell junctions are often linked to p38 activation. Consistent
with our observation of actin cytoskeletal reorganisation, p38 is report-
edly involved in cytoskeletal destabilisation and changes in endothelial
cell permeability (Li et al., 2015; Koss et al., 2006). In addition, tight
junction proteins can be modulated by chemokines and
mitogen-activated protein kinase (MAPK) signalling and cytoskeletal
rearrangement are involved in the process (Hudson et al., 2014; Shaha-
buddin et al., 2006). Accordingly, p38 has been shown previously to
modulate the expression and distribution of tight junction proteins,
including ZO-1, linking this signalling pathway into the regulation of
vascular permeability. Indeed, MAPK kinases are involved in
co-modulating tight junction protein phosphorylation and thus are able
to regulate paracellular transport and hence barrier permeability (Gon-
zalez-Mariscal et al., 2008).
Chemokines can disturb the organization of junctions in endothelial
cells (Gonzalez-Mariscal et al., 2008; Wallez and Huber, 2008). For
example, in brain endothelial cells recent work has shown that the che-
mokine CCL2 disrupts tight junctions, including altering ZO-1 distribu-
tion, and that this results in increased BBB permeability (Dimitrijevic
et al., 2006; Luissint et al., 2012). Similarly CKLF1, a C–C chemokine, has
been shown to be involved in downregulation of ZO-1 expression and
BBB disruption (Kong et al., 2016). Our study adds CCL4 to this list of
junction modulating chemokines as it clearly affected junctional local-
isation of ZO-1, contributing to the observed induction of barrier
dysfunction. These data suggest that junctional ZO-1 is a common
downstream signalling target for a number of chemokines and demon-
strates their potential importance in disease pathology.
VE-cadherin is also a key mediator of endothelial barrier dysfunction
and paracellular leakage (Orsenigo et al., 2012). Its phosphorylation and
internalisation lies at the end of many angiogenic, vasogenic and
pro-inflammatory signal transduction cascades (Esser et al., 1998). Here,
we establish that CCL4 also changes the spatial distribution of
VE-cadherin. To the best of our knowledge, this is the first report
demonstrating that VE-cadherin is redistributed in response to a CCL
chemokine. VE-cadherin redistribution was profound and its manifesta-
tions consistent with epitope masking (catenins bind within the C-ter-
minal epitope recognition area) and more importantly internalisation, as
also described previously (Dragoni et al., 2021). VE-cadherin internal-
isation is generally triggered by its phosphorylation and is a pre-requisite
of vascular leakage in the periphery (Orsenigo et al., 2012) but also the
retinal microvasculature (Dragoni et al., 2021; Ninchoji et al., 2021) in9
response to VEGF. Consistent with this, phosphorylation of VE-cadherin
and loss of barrier integrity has also shown to facilitate increased
leukocyte migration via the paracellular route (Wessel et al., 2014;
Martinelli et al., 2014; Turowski et al., 2008). Indeed, ICAM-1 cross-
linking on BBB ECs, to mimic leukocyte adhesion, resulted in internal-
isation of VE-cadherin within 5 min (Dragoni et al., 2017). In contrast,
stabilization of the VE-cadherin/catenin complex has been shown to
hinder permeability and leukocyte extravasation (Schulte et al., 2011).
CCL4 has been reported to be expressed by BBB endothelial cells in
response to ICAM-1 crosslinking, mimicking the molecular effects of
lymphocyte migration (Dragoni et al., 2017). The findings in this report
have shown that CCL4 has an effect on brain ECs in allowing increased
lymphocyte migration, suggesting that there could be an autocrine
amplification loop leading to sustained barrier dysfunction.
In this report, we show that VE-cadherin redistribution in hCMEC/D3
cells coincided with enhanced permeability and lymphocyte trans-
migration induced by CCL4. Overall, this may have wide implications for
our understanding of neuroinflammation.
5. Conclusion
Throughout our experiments, CCL4 showed consistently strong ef-
fects on junctional protein and barrier function demonstrating its ca-
pacity to modify CNS vascular permeability and neuroinflammation. Our
data is consistent with current literature and highlights a potentially
important role for chemokines directly affecting brain vascular endo-
thelial cell function.
The data presented in this paper supports a role of CCL4 in the
pathogenesis of neuroinflammatory and neurodegenerative diseases. In
relation to neuropsychiatric conditions, it raises the intriguing possibility
that CCL4 will contribute to their aetiology. From a clinical point of view,
major depressive disorder (MDD) and posttraumatic stress disorder
(PTSD) are characterized by raised levels of inflammation, hypothalamic-
pituitary-adrenal axis disfunction and reduced neurogenesis. Depressed
individuals have shown to have lower levels of CCL4 than healthy in-
dividuals (Leighton et al., 2018; Lehto et al., 2010). In fact, one study
found lower levels of CCL4 in the CSF of individuals who attempted
suicide when compared with health control subjects (Janelidze et al.,
2013). A recent meta-analysis showed that patients diagnosed with PTSD
have lower levels of CCL4 than healthy controls (Pan et al., 2021). In
contrast, CCL4 levels may be increased in other neuro-psychiatric dis-
orders such as schizophrenia (Beumer et al., 2012; Frydecka et al., 2018).
Another study focusing on biomarkers to differentiate unipolar and bi-
polar disorder, found that patients diagnosed with bipolar disorder, had
high levels of CCL4 than unipolar counterparts (Poletti et al., 2021).
Altogether, there can be a biomarker or therapeutical potential in
investigating further the role of abnormal levels of CCL4, its effect on BBB
permeability and neurogenesis.
Abnormal levels of chemokines are also found in MS patients. CCL4
has been established as a marker for MS and correlates well with disease
duration (Ghafouri-Fard et al., 2021). Pertinent to this body of work,
various CCL chemokines have been identified in frontal lobe sections
(Subileau et al., 2009), chronic active MS lesions and astrocytes in the
CNS of patients with MS (Simpson et al., 2000), suggesting an active role
of these chemokines, and by extension of the findings in this report,
CCL4, in disease pathogenesis.
CCL4 may also influence neurogenesis; an agonist against CCL4's re-
ceptor, CCR5, facilitated neurogenesis in seizure-induced injury in the
CNS (Louboutin and Strayer, 2013). These effects may be due to a
dampening of the inflammatory processes due to the blocking of CCR5
that, as mentioned above, is known to limit neurogenesis. Of note, a
decrease in the expression of this receptor in circulating immune cells
reduced BBB leakage and inflammation and promoted neurogenesis
rendering the mice less susceptible to seizures (Louboutin et al., 2011).
Altogether, our results suggest a potential for CCL4 as a novel
modulating factor in BBB endothelial cells.
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